InvestorsHub Logo
Followers 185
Posts 2462
Boards Moderated 0
Alias Born 02/10/2017

Re: None

Friday, 01/15/2021 9:32:49 AM

Friday, January 15, 2021 9:32:49 AM

Post# of 238
$7.00+ is in the cards today they just got more cash. Looking for ARKG to buy more soon watch and learn how this works. We just broke new highs and a 5 year high yesterday. This chart is just starting to launch


EVGN under the radar name gearing up for double digit dollars stock will be explosive soon.


70 million cash no debt.


a product commercially ready early next year that will take massive market share from Monsanto roundup a green friendly product.


How Much Money Does Monsanto Make From Roundup:


How much money does Monsanto make from Roundup? In 2015, the company made nearly $4.76 billion in sales and $1.9 billion in gross profits


EVGN is a leading computational biology gene editing AI company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform.

EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf


Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders



$EVGN
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EVGN News